Solana Company reported third quarter 2025 revenue of $0.7 million, which included $0.3 million in first-time staking rewards income. Cost of revenue was $0.1 million, a decrease from $0.2 million in the prior-year period. Selling, general, and administrative expenses rose to $4.6 million from $2.9 million, mainly due to a $1.5 million discretionary bonus. Research and development expenses decreased to $0.9 million from $1.1 million, attributed to reduced clinical trial activities. The company reported an unrealized loss on digital assets of $30.5 million due to changes in the fair value of holdings. During the quarter, Solana Company closed a $508 million PIPE transaction and secured over $500 million in funding through partnerships with Pantera Capital and Summer Capital. The company also launched an ATM program, issued cash-exercise warrants with a potential aggregate raise of $750 million, and approved a stock repurchase program of up to $100 million. Additional business developments included the submission of an FDA 510(k) designation for PoNS device label expansion and the announcement of positive clinical data demonstrating the device's effectiveness in improving gait deficit.